NCT05082974已完成3 期
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Laser-assisted in Situ Keratomileusis (LASIK)
Vance Thompson Vision ND1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年10月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Change in NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire) score
研究概览
简要总结
Evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray for amelioration of signs and symptoms of dry eye disease in subjects following laser-assisted in situ keratomileusis (LASIK).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be willing and able to sign the informed consent form (ICF)
- •Be at least 18 years of age at the screening visit
- •Be undergoing LASIK treatment in one or both eyes
- •Be myopic between -1.00D to -7.00D MRSE (manifest refraction spherical equivalent) in study eye (right eye) with ≤2D between eyes or subjects undergoing monovision treatment with study eye (distance eye) meeting the diopter requirement of myopia
- •Be literate and able to complete questionnaires independently
- •Be able and willing to use the study drug and participate in all study assessments and visits
- •Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug
- •Have provided verbal and written informed consent
- •If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on baseline
排除标准
- •Subjects must not:
- •Have a break in the integrity of the corneal epithelium such as a persistent corneal epithelial defect, or corneal ulcer.
- •Have presence of corneal pathology that may interfere with LASIK outcomes
- •Active infectious, ocular or systemic disease
- •Have a history of ocular inflammation or macular edema
- •Have had clinically significant active infectious keratitis in the past 3 months
- •Have history of prior refractive surgery
- •Have placement of temporary punctal plugs in the past 1 month or current presence of permanent punctal plugs at time of screening
- •Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to clinically significant risk of increased bleeding
- •Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
- •Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction as confirmed by intranasal examination performed at Visit
- •Be currently treated with nasal continuous positive airway pressure
- •Have had blepharoplasty in either eye
- •Have had a corneal transplant in either eye
- •Have a history of seizures or other factors that lower the subject's seizure threshold.
- •Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- •Have a known hypersensitivity to any of the procedural agents or study drug components
- •Have current concomitant use of a nicotinic acetylcholine receptor agonist [Nicoderm®, Nicorette®, Nicotrol NS® (nicotine), Tabex®, Desmoxan® (cytisine), and Chantix® (varenicline)] within the previous 30 days of Visit 1 and during the treatment period.
- •Have current concomitant use of snuff, chewing tobacco, e-cigarettes or cigarettes/cigars during the study or within the previous 30 days.
- •Subject must refrain from smoking during the course of the study.
- •Have active or uncontrolled, severe at the discretion of the investigator:
- •Systemic allergy
- •Chronic seasonal allergies at risk of being active during the study treatment period
- •Rhinitis or sinusitis requiring treatment such as antihistamines, decongestants, oral or aerosol steroids at the Screening Visit or be expected to require treatment during the treatment period of the study
- •Untreated nasal infection at Visit 1
- •Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
- •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.
- •Be a female who is pregnant, nursing, or planning a pregnancy at Visit
- •Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner or hysterectomy. A woman that has not had a menses in 12 months or longer is not considered of childbearing potential.
研究组 & 干预措施
OC-01 (varenicline 0.6mg/ml) nasal spray
Experimental
干预措施: OC-01 (varenicline 0.6mg/ml) nasal spray (Drug)
Placebo (vehicle) nasal spray
Placebo Comparator
干预措施: Placebo (vehicle) nasal spray (Drug)
结局指标
主要结局
Change in NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire) score
时间窗: Baseline to Day 84 (3 months)
25 questions to determine overall score of dry eye disease symptoms completed by subject. Scored from 0-100, with 100 being the highest score and best outcome.
Mean change in corneal fluorescein staining based on the NEI (National Eye Institute) scale for Corneal Fluorescein Staining determined at slit lamp
时间窗: Baseline to Surgical Day and from Surgical Day to Day 84 (3-month)
Evaluated at slit lamp by a masked physician
次要结局
- Mean change in residual refractive error(Day 28 (1-month) postoperative LASIK over time to Day 84 (3-month) postoperative LASIK)
- Change in tear collection lab values(Day 28 (1-month) postoperative LASIK over time to Day 84 (3-month))
- Mean change tear break-up time(baseline to Day 0 (Surgical Day), Day 28 (1-month) postoperative LASIK and Day 84 (3-month) postoperative LASIK)
- Incidence and severity of adverse events(Screening to Day 168 (6-month postoperative LASIK))
- Change in NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire) score(Baseline to Day 184 (6 months))
- Mean change in eye dryness score (EDS)(Baseline to Day 184 (6 months))
- Proportion of subjects treated with rescue dry treatment and/or punctal plugs(Day 84 (3-months) postoperative and Day 168 (6-months) postoperative LASIK)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)Dry EyeNCT05045508Brandon Baartman60
已完成
2 期
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic KeratopathyNeurotrophic KeratopathyNCT04957758Oyster Point Pharma, Inc.113
已完成
2 期
Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseaseDry Eye DiseaseNCT03636061Oyster Point Pharma, Inc.182
已完成
3 期
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye DiseaseDry Eye Disease (DED)NCT04036292Oyster Point Pharma, Inc.758
已完成
2 期
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland StimulationDry Eye DiseaseNCT03688802Oyster Point Pharma, Inc.18